Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Friday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Barclays decreased their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

Shares of CLLS stock opened at $1.67 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $1.98. The stock has a market capitalization of $92.82 million, a price-to-earnings ratio of -1.28 and a beta of 3.08. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the prior year, the business posted ($0.31) earnings per share. On average, analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CLLS. XTX Topco Ltd purchased a new position in shares of Cellectis in the 2nd quarter valued at approximately $29,000. First Affirmative Financial Network acquired a new position in Cellectis during the 3rd quarter valued at approximately $45,000. Finally, Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.